Last reviewed · How we verify
MB-CART2019.1
At a glance
| Generic name | MB-CART2019.1 |
|---|---|
| Also known as | CD20/CD19-targeting CAR T cells, Anti-CD20/CD19 CAR T cells |
| Sponsor | Miltenyi Biomedicine GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- DALY II Japan/MB-CART2019.1 for DLBCL (PHASE2)
- Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (PHASE2)
- Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms (PHASE2)
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies (NA)
- MB-CART2019.1 in Refractory Multiple Sclerosis (PHASE1, PHASE2)
- Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (PHASE1)
- DALY II USA/ MB-CART2019.1 for DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-CART2019.1 CI brief — competitive landscape report
- MB-CART2019.1 updates RSS · CI watch RSS
- Miltenyi Biomedicine GmbH portfolio CI